The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: Results from a randomized placebo‑controlled trial

International Journal of Bipolar Disorders

Volumn 4, Issue 1, 2016, Pages

  Rajagopalan, Krithika ^a   Bacci, Elizabeth Dansie ^b   Wyrwich, Kathleen W ^b   Pikalov, Andrei ^a   Loebel, Antony ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b EVIDERA   (United States)

Author keywords

Bipolar disorder; Depression; Patient functioning; Sheehan disability scale

Indexed keywords

LURASIDONE; PLACEBO;

ADULT; ARTICLE; BIPOLAR DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL DISEASE; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHEEHAN DISABILITY SCALE;

EID: 85019633024     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/s40345-016-0049-1     Document Type: Article

References (35)

1. Altshuler LL, Post RM, Black DO, Keck PE Jr, Nolen WA, Frye MA, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67(10):1551-60.
2. Arbuckle R, Frye MA, Brecher M, Paulsson B, Rajagopalan K, Palmer S, et al. The psychometric validation of the Sheehan disability scale (SDS) in patients with bipolar disorder. Psychiatry Res. 2009;165(1-2):163-74. doi:10.1016/j. psychres.2007.11.018.
3. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173-82.
4. Burdick KE, Goldberg JF, Harrow M. Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at 15-year follow-up. Acta Psychiatr Scand. 2010;122(6):499-506. doi:10.1111/j.1600-0447.2010.01590.x.
5. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry. 2004;65(11):1499-504.
6. Depp CA, Mausbach BT, Bowie C, Wolyniec P, Thornquist MH, Luke JR, et al. Determinants of occupational and residential functioning in bipolar disorder. J Affect Disord. 2012;136(3):812-8. doi:10.1016/j.jad.2011.09.035.
7. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-6.
8. Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Reg. 2009;74(235):65132-3.
9. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York: Oxford University Press; 2007.
10. Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010;24(4):267-84. doi:10.2165/11530230-000000000-00000.
11. Gutierrez-Rojas L, Jurado D, Gurpegui M. Factors associated with work, social life and family life disability in bipolar disorder patients. Psychiatry Res. 2011;186(2-3):254-60. doi:10.1016/j.psychres.2010.06.020.
12. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5.
13. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-96.
14. Harvey PD. Mood symptoms, cognition, and everyday functioning: in major depression, bipolar disorder, and schizophrenia. Innov Clin Neurosci. 2011;8(10):14-8.
15. Henry BL, Minassian A, Perry W. Everyday functional ability across different phases of bipolar disorder. Psychiatry Res. 2013;210(3):850-6. doi:10.1016/j.psychres.2013.04.006.
16. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis. conventional criteria versus new alternatives. Struct Equ Model. 1999;6:1-55.
17. Keck PE Jr. Defining and improving response to treatment in patients with bipolar disorder. J Clin Psychiatry. 2004;65(Suppl 15):25-9.
18. Kenny DA. Mediation. 2014. http://www.davidakenny.net/cm/mediate.htm. Accessed 28 Feb 2014.
19. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006;163(9):1561-8. doi:10.1176/appi.ajp.163.9.1561.
20. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014a;171(2):169-77.
21. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, doubleblind, placebo-controlled study. Am J Psychiatry. 2014b;171(2):160-8.
22. Loebel A, Siu C, Rajagopalan K, Pikalov A, Cucchiaro J, Ketter TA. Recovery in bipolar depression: post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. J Affect Disord. 2015;186:376-82. doi:10.1016/j.jad.2015.07.033.
23. MacCallum RC, Browne MW, Sugawara HM. Power analysis and determination of sample size for covariance structure modeling. Psychol Methods. 1996;1:130-49.
24. Miklowitz DJ. Functional impairment, stress, and psychosocial intervention in bipolar disorder. Curr Psychiatry Rep. 2011;13(6):504-12. doi:10.1007/ s11920-011-0227-x.
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Mental Sci. 1979;134:382-9.
26. Muthén LK, Muthén BO. Mplus user’s guide. 7th ed. Los Angeles; 1998-2013.
27. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health J Int Soc Pharmacoecon Outcomes Res. 2010;13(8):984-8. doi:10.1111/j.1524-4733.2010.00768.x.
28. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-83.
29. Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol. 2008;23(2):70-83. doi:10.1097/YIC.0b013e3282f2b4d6.
30. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89-95.
31. Sheehan DV, Chokka PR, Granger RE, Walton RJ, Raskin J, Sagman D. Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. Hum Psychopharmacol. 2011;26(3):242-51. doi:10.1002/hup.1199.
32. Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry. 2007;68(8):1237-45.
33. Tohen M, Hennen J, Zarate CM Jr, Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of firstepisode major affective disorder with psychotic features. Am J Psychiatry. 2000;157(2):220-8.
34. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96. doi:10.1016/ S0140-6736(12)61729-2.
35. Wise TN, Meyers AL, Desaiah D, Mallinckrodt CH, Robinson MJ, Kajdasz DK. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. Primary Care Companion J Clin Psychiatry. 2008;10(4):270-5.